文献速递糖尿病性腺与生殖内分泌

比较晚期混合闭环疗法与标准胰岛素治疗在1型糖尿病孕妇中的效果(CRISTAL):平行组、开放标签、随机对照试验

Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-04-30

CRISTAL研究在12家医院将95例1型糖尿病孕妇随机分至MiniMed 780G晚期混合闭环(AHCL)疗法组或标准胰岛素治疗组,主要终点为目标血糖范围内时间比例在两组间无显著差异,但AHCL组夜间目标范围内时间更高、低于范围时间更少、治疗满意度更高。

要点

  • AHCL组与标准组平均目标范围内时间比例无显著差异(66.5% vs 63.2%,校正均差1.88个百分点,p=0.17)。
  • AHCL组夜间目标范围内时间更高(校正均差6.58个百分点,p=0.0026),总体及夜间低于范围时间更少。
  • AHCL组治疗满意度更高,未发生非预期安全事件;作者认为MiniMed 780G可安全用于妊娠,但需优化算法。

核心结论

  • 在起始血糖控制较紧的1型糖尿病孕妇中,AHCL疗法未改善总体目标范围内时间,但改善了夜间目标范围内时间、减少了低于范围时间并提高了治疗满意度。
  • 作者认为MiniMed 780G可安全用于妊娠,与标准胰岛素治疗相比提供了一些额外获益,但优化算法以更好契合妊娠需求很重要。

研究设计与样本

  • CRISTAL为双臂、平行组、开放标签、随机对照试验,在12家医院(比利时11家、荷兰1家)的二级和三级专科内分泌中心进行。
  • 18-45岁1型糖尿病孕妇按1:1随机分配至AHCL疗法(MiniMed 780G)或标准胰岛素治疗(标准治疗),随机化在中位孕10.1周(IQR 8.6-11.6)进行。
  • 随机化采用中心化方法,按基线HbA1c、胰岛素给药方式和中心进行最小化,参与者和研究团队对分组分配未设盲。
  • 共筛查101例,95例随机分配至AHCL组(n=46)或标准胰岛素组(n=49),AHCL组43例和标准组46例完成研究;分析基于意向性治疗。
  • 主要结局为妊娠特异性目标血糖范围(3.5-7.8 mmol/L)内时间比例,通过持续葡萄糖监测(CGM)在14-17周、20-23周、26-29周和33-36周测量。

主要发现

  • 基线时91例(95.8%)参与者使用胰岛素泵,平均HbA1c为6.5%(SD 0.6)。
  • 四个时间段平均的目标范围内时间比例在AHCL组为66.5%(SD 10.0),标准胰岛素组为63.2%(12.4),校正均差1.88个百分点(95% CI -0.82至4.58),p=0.17。
  • 夜间目标范围内时间AHCL组较标准组更高,校正均差6.58个百分点(95% CI 2.31至10.85),p=0.0026。
  • 总体低于范围时间(<3.5 mmol/L)AHCL组较标准组更低,校正均差-1.34个百分点(95% CI -2.19至-0.49),p=0.0020;夜间低于范围时间AHCL组较标准组更低,校正均差-1.86个百分点(95% CI -2.90至-0.81),p=0.0005。
  • 分配至AHCL疗法的参与者报告更高的治疗满意度,AHCL疗法未发生非预期安全事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Advanced hybrid closed loop (AHCL) therapy can improve glycaemic control in pregnant women with type 1 diabetes. However, data are needed on the efficacy and safety of AHCL systems as these systems, such as the MiniMed 780G, are not currently approved for use in pregnant women. We aimed to investigate whether the MiniMed 780G can improve glycaemic control with less hypoglycaemia in pregnant women with type 1 diabetes. METHODS: CRISTAL was a double-arm, parallel-group, open-label, randomised controlled trial conducted in secondary and tertiary care specialist endocrinology centres at 12 hospitals (11 in Belgium and one in the Netherlands). Pregnant women aged 18-45 years with type 1 diabetes were randomly assigned (1:1) to AHCL therapy (MiniMed 780G) or standard insulin therapy (standard of care) at a median of 10·1 (IQR 8·6-11·6) weeks of gestation. Randomisation was done centrally with minimisation dependent on baseline HbA1c, insulin administration method, and centre. Participants and study teams were not masked to group allocation. The primary outcome was proportion of time spent in the pregnancy-specific target glucose range (3·5-7·8 mmol/L), measured by continuous glucose monitoring (CGM) at 14-17 weeks, 20-23 weeks, 26-29 weeks, and 33-36 weeks. Key secondary outcomes were overnight time in target range, and time below glucose range (<3·5 mmol/L) overall and overnight. Analyses were conducted on an intention-to-treat basis. This trial is registered with ClinicalTrials.gov (NCT04520971). FINDINGS: Between Jan 15, 2021 and Sept 30, 2022, 101 participants were screened, and 95 were randomly assigned to AHCL therapy (n=46) or standard insulin therapy (n=49). 43 patients assigned to AHCL therapy and 46 assigned to standard insulin therapy completed the study. At baseline, 91 (95·8%) participants used insulin pumps, and the mean HbA1c was 6·5% (SD 0·6). The mean proportion of time spent in the target range (averaged over four time periods) was 66·5% (SD 10·0) in the AHCL therapy group compared with 63·2% (12·4) in the standard insulin therapy group (adjusted mean difference 1·88 percentage points [95% CI -0·82 to 4·58], p=0·17). Overnight time in the target range was higher (adjusted mean difference 6·58 percentage points [95% CI 2·31 to 10·85], p=0·0026), and time below range overall (adjusted mean difference -1·34 percentage points [95% CI, -2·19 to -0·49], p=0·0020) and overnight (adjusted mean difference -1·86 percentage points [95% CI -2·90 to -0·81], p=0·0005) were lower with AHCL therapy than with standard insulin therapy. Participants assigned to AHCL therapy reported higher treatment satisfaction. No unanticipated safety events occurred with AHCL therapy. INTERPRETATION: In pregnant women starting with tighter glycaemic control, AHCL therapy did not improve overall time in target range but improved overnight time in target range, reduced time below range, and improved treatment satisfaction. These data suggest that the MiniMed 780G can be safely used in pregnancy and provides some additional benefits compared with standard insulin therapy; however, it will be important to refine the algorithm to better align with pregnancy requirements. FUNDING: Diabetes Liga Research Fund and Medtronic.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Benhalima K, Beunen K, Van Wilder N, et al. Comparing advanced hybrid closed loop therapy and standard insulin therapy in pregnant women with type 1 diabetes (CRISTAL): a parallel-group, open-label, randomised controlled trial. Lancet Diabetes Endocrinol. 2024. PMID: 38697182. doi:10.1016/S2213-8587(24)00089-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。